Cardiac amyloidosis: a Cochrane protocol plans to assess tafamidis and acoramidis

Tafamidis and acoramidis will be the subject of a Cochrane review on transthyretin amyloid cardiomyopathy, or ATTR-CM. But the available publication is a protocol: it describes the planned questions and comparisons without providing a new estimate of their effectiveness.

Illustration of the heart accompanying a news article on the assessment of treatments for transthyretin cardiac amyloidosis.
SupplementsEditorial illustration, not study data.

A planned assessment, not results

The primary objective is to assess the effects of these two transthyretin-stabilizing drugs on all-cause mortality and hospitalizations for heart failure in people with ATTR-CM.

The planned comparator is usual care or a placebo. The abstract does not describe a direct comparison between tafamidis and acoramidis. It therefore cannot establish which would be preferable.

Differences between patients will be examined

The authors also plan to examine effects by sex, ethnicity, disease form and severity. In particular, they will distinguish between wild-type and variant transthyretin forms, as well as NYHA functional classes.

These analyses are stated objectives. Their inclusion in the protocol does not guarantee that the available studies will support conclusions for each of these subgroups.

What this publication changes

Its contribution is to make the framework for the upcoming assessment explicit. The abstract consulted provides no pooled results, total participant count, follow-up duration or summary of adverse effects.

This publication is therefore not enough to justify changing a treatment or concluding that there is no benefit. It concerns medicines, not dietary supplements.

Limitations to keep in mind

Only the protocol’s PubMed abstract was consulted, not the full text. It presents no efficacy or safety results. Funding and conflicts of interest were not checked.

What we can take away

Takeaway: this protocol announces an assessment of two treatments for ATTR-CM, but does not yet demonstrate their benefits or whether either is superior to the other.

Sources and provenance

Partager cet article

X f in

An error or a source to report? Contact the editorial team.